ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Association between Response to Rituximab and Risk of Antibody-Mediated Rejection in ABO-Incompatible Living Kidney Transplantation

Y. Kakuta1, M. Okumi1, T. Kanzawa1, K. Unagami2, H. Ishida2, K. Tanabe1

1Urology, Tokyo Women's Medical University, Tokyo, Japan, 2Organ Transplant Regulation, Tokyo Women's Medical University, Tokyo, Japan

Meeting: 2020 American Transplant Congress

Abstract number: D-085

Keywords: Antibodies, CD20, Kidney, Rejection

Session Information

Session Name: Poster Session D: Kidney Immunosuppression: Desensitization

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Owing to limited organ availability, ABO-incompatible living kidney transplantation (ABO-ILKT) has been used extensively. Various forms of preconditioning therapies have been used alone or in combination. We examined the association of response to rituximab and incidence of antibody-mediated rejection (AMR) in preconditioning of rituximab and plasmapheresis (PP) without posttransplant plasmapheresis.

*Methods: We selected 225 patients who underwent ABO-ILKT between January 2005 and December 2015 at our institute. We excluded 110 patients owing to the following reasons: lack of data on lymphocyte subsets during the perioperative period, no use of rituximab, and positive DSA. The remaining 115 patients were divided into two groups based on the response to rituximab: well-response (n = 75) or poor-response (n = 40). The rituximab well-response and poor-response patient were defined as the patient whose CD19+ cells were non-detected (0%) and detected on the day of transplantation (2-5 days (median 3days) after rituximab administration), respectively. Rituximab was administered as a single dose (200 mg) within 2-5 d (median 3 d) prior to the operation. All patients underwent PP before surgery to reduce anti-A/B antibody to less than or equal to the titer of <1:32

*Results: Poor-response recipients had much higher CD19+ cells even after transplantation than well-response recipients. Univariate analysis indicated that rituximab response was a potential significant risk factor of AMR. A multivariate analysis indicated that rituximab response and anti-A/B blood antibody titer after PP were both significant risk factors of AMR (p=0.036, 0.045, respectively).The occurrence of AMR was higher in the poor-response group than in the well-response group (22.5% vs. 8.0%; p=0.028). The 14-day, 3-month and 1-year cumulative incidence of AMR was 2.7%, 5.3% and 8.0% in the well-response group, and 17.5%, 20.0% and 22.5% in the poor-response group after ABO-ILKT (p=0.022, log-rank test). In pathological findings, C4d and MVI (g + ptc) were higher in the poor response group than in the well response group. The patient and graft survival were not significantly different between the two groups. However, graft survival 1 month after transplantation was lower in the poor-response group. There is no significant difference in incidence of infection and complication after transplantation between two groups. No patients with febrile neutropenia was observed in rituximab poor-response group.

*Conclusions: The response to rituximab was significantly associated with the incidence of AMR. In our preconditioning protocol using antibody removal therapy and rituximab without postoperative apheresis, enough CD19 depletion by rituximab may be important to suppress AMR in ABO-ILKT.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Kakuta Y, Okumi M, Kanzawa T, Unagami K, Ishida H, Tanabe K. Association between Response to Rituximab and Risk of Antibody-Mediated Rejection in ABO-Incompatible Living Kidney Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/association-between-response-to-rituximab-and-risk-of-antibody-mediated-rejection-in-abo-incompatible-living-kidney-transplantation/. Accessed June 6, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences